Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026)

Verano Holdings (VRNO) reported Total Non-Current Liabilities of $902.9 million for Q1 2026, up 5.02% year-over-year from $859.7 million in Q1 2025, and little changed quarter-over-quarter from $899.0 million in Q4 2025.

Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has 6 years of Total Non-Current Liabilities data on file, last reported at $902.9 million in Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $902.9 million, up 5.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $902.9 million (up 5.02% YoY), and the FY2025 annual result was $899.0 million, up 7.0% from the prior year.
  • Total Non-Current Liabilities steadied at $902.9 million in Q1 2026 per VRNO's latest filing, from $899.0 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $902.9 million in Q1 2026 and troughed at $469.5 million in Q2 2022.
  • A 5-year average of $736.3 million and a median of $680.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 43.17% in 2023, then slipped 4.02% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $667.9 million in 2022, then decreased by 0.21% to $666.5 million in 2023, then grew by 26.06% to $840.2 million in 2024, then grew by 7.0% to $899.0 million in 2025, then increased by 0.44% to $902.9 million in 2026.
  • Business Quant data shows VRNO's Total Non-Current Liabilities at $902.9 million in Q1 2026, $899.0 million in Q4 2025, and $897.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 18.28 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 11.64 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 599.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 44.12 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 1.24 Bn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 6.26 Bn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 2.44 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 1.81 Bn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 1.13 Bn
10 Verano Holdings - - 98.98 Mn 902.87 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 902.87 Mn
Dec 31, 2025 898.95 Mn
Sep 30, 2025 897.85 Mn
Jun 30, 2025 868.42 Mn
Mar 31, 2025 859.73 Mn
Dec 31, 2024 840.17 Mn
Sep 30, 2024 661.59 Mn
Jun 30, 2024 657.07 Mn
Mar 31, 2024 661.13 Mn
Dec 31, 2023 666.48 Mn
Sep 30, 2023 689.32 Mn
Jun 30, 2023 672.14 Mn
Mar 31, 2023 669.11 Mn
Dec 31, 2022 667.86 Mn
Sep 30, 2022 698.54 Mn
Jun 30, 2022 469.47 Mn
Dec 31, 2021 596.33 Mn